Radiopharmaceuticals Market

Global Radiopharmaceuticals Market Size 

The Global Radiopharmaceuticals Market is projected to grow from USD 20.68 billion in 2025 to USD 23.41 billion in 2026 and reach USD 63.13 billion by 2034, registering a CAGR of 13.20% from 2026 to 2034.

MARKET DRIVERS

The growing patient population suffering from chronic diseases worldwide primarily propels the growth of the Radiopharmaceuticals Market.

The prevalence of chronic diseases such as cancer, CVDs, diabetes, and others is growing significantly worldwide. Patients suffering from these diseases require continuous health monitoring to identify the progression of the diseases, gain an understanding of treatment efficacy and find other potential risks. Nuclear medicine helps diagnose and manage chronic diseases as it provides valuable information on abnormalities at an early stage, which provides a way for healthcare providers to plan an appropriate intervention for disease management. Considering the same, healthcare providers and patients prefer nuclear medicine for effective disease management. The World Health Organization says one in six people dies of cancer worldwide, and around 10 million died in 2020. In addition, the growing aging population worldwide is expected to boost the Radiopharmaceuticals Market growth. People who age are much more likely to diagnose with various chronic diseases and need diagnostic imaging, which is expected to promote the need for nuclear medicine and boost the market growth. WHO says one in six people will be more than 60 years by 2030 worldwide, and the total aging population is expected to reach 1.4 billion.

The growing adoption of technological developments to develop further advancements in nuclear medicine is expected to fuel the market’s growth rate.

Some notable developments in nuclear medicine are PET-CT and SPECT-CT, due to which healthcare providers can now take detailed, accurate, and precise images of the inside of the body. Using these imaging modalities, the early detection of diseases is possible and can also be delivered improved patient outcomes.Furthermore, growing demand for non-invasive diagnostic procedures, increasing support from various governments in favor of nuclear medicine, and rising investments to conduct R&D and develop advanced nuclear medicine procedures are expected to promote the growth rate of the global market.

MARKET RESTRAINTS

Strict regulatory policies coupled with growing competition from conventional alternatives act as market restraints for nuclear medicine diagnostics' growth during the forecast period. In addition, the high cost of equipment and diagnostics will become the biggest challenge for market growth.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Type Insights

Based on type, the Fluorine-18 segment accounted for the largest share of the PET radiopharmaceuticals Radiopharmaceuticals Market in 2025. The segment's domination will likely continue during the forecast period owing to the growing adoption of F-18. The growing usage of Fluorine-18 in PET imaging to diagnose various chronic diseases further contributes to segmental growth. In addition, using Fluorine-18, rapid imaging is possible and can take high-quality inside images. The domination of F-18 is expected to continue during the forecast period owing to the growing prevalence of cancer worldwide.

By Application Insights

Based on the application, the oncology segment is expected to witness the highest CAGR over the forecast period. Although nuclear medicine can help cure many diseases, the usage of nuclear medicine is high in treating cancer, which is majorly propelling segmental growth. Healthcare providers need to find the type, location, and extent of cancer to develop an effective treatment plan for patients, in which nuclear medicine can be of great help. In addition, nuclear medicine further helps healthcare providers in the disease management of cancer by providing information on treatment effectiveness. Likewise, the growing usage of nuclear medicine in cancer treatment is driving the growth of the oncology segment. Therefore, this segment is expected to register promising growth during the forecast period.  

REGIONAL ANALYSIS

North America accounted for the largest share of the worldwide market in 2025, and the region's domination is anticipated to continue during the forecast period. The U.S. held a significant share of the North American market in 2021 and is expected to maintain its dominance due to the increased number of procedures and use of nuclear medicine isotopes for different therapeutic applications. Canada is Technetium-99 m's largest manufacturer. The market will likely expand tremendously in Canada because of the use of Tc-99 m in radiopharmaceuticals. In various diagnostic procedures and treatments, 80% of the Radiopharmaceuticals Market is driven by Tc-99 m. Therefore, the North American market will likely witness promising CAGR and dominance in the global market.

The European region occupied a considerable share of the worldwide market in 2025 and is expected to grow at a considerable CAGR during the forecast period. Cancer prevalence is growing significantly in the European region. An estimated 23.4% of the cancer cases populating worldwide are from Europe. The growing prevalence of cancer in Europe is anticipated to result in the increasing usage of nuclear medicine and boost regional market growth.

The APAC regional market is predicted to register the highest CAGR in the global market in the coming years. This is because of the growing patient volume suffering from chronic diseases, an increasing number of developments in the healthcare infrastructure, growing adoption of nuclear medicine, increasing awareness among healthcare providers regarding the benefits of nuclear medicine, rising aging population, increasing adoption of technological developments, and a growing number of initiatives from the governments to promote nuclear medicine are propelling the Radiopharmaceuticals Market in APAC.

Latin America is projected to hold a considerable share of the global market during the forecast period. The Latin American region has been experiencing substantial R&D investments in developing the healthcare infrastructure, and the prevalence of chronic diseases in this region is growing rapidly; such factors are anticipated to boost the Radiopharmaceuticals Market growth in Latin America.

KEY MARKET PLAYERS 

Cardinal Health, Inc., Bracco Imaging S.p.A, GE Healthcare, Eczacibasi-Monrol Nuclear Products, Nordion, Inc., Bayer Healthcare, Lantheus Medical Imaging, Inc., Advanced Accelerator Applications S.A., IBA Molecular Imaging and Mallinckrodt PLC.

MARKET SEGMENTATION

This research report on the global radiopharmaceuticals market has been segmented and sub-segmented based on the type, application, and region.

By Type

• SPECT

  • Technetium-99m

  • Thallium-201

  • Gallium-67

  • Iodine-23

  • Others

• PET

  • Fluorine-18

  • Rubidium-82

  • Others

By Application

• Cardiology

• Lymphoma

• Thyroid

• Neurology

• Oncology

• Others

By Region

• North America

• Europe

• Asia-Pacific

• Latin America

• The Middle East and Africa